Aquestive Therapeutics Inc (NASDAQ: AQST) is 101.49% higher on its value in year-to-date trading and has touched a low of $1.10 and a high of $6.23 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AQST stock was last observed hovering at around $4.09 in the last trading session, with the day’s loss setting it -0.02%.
Currently trading at $4.07, the stock is -11.20% and 8.16% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.15 million and changing -0.49% at the moment leaves the stock 76.28% off its SMA200. AQST registered 257.02% gain for a year compared to 6-month gain of 208.33%. The firm has a 50-day simple moving average (SMA 50) of $7.41 and a 200-day simple moving average (SMA200) of $317.02.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -17.61% loss in the last 1 month and extending the period to 3 months gives it a 49.63%, and is -7.08% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.70% over the week and 8.39% over the month.
Aquestive Therapeutics Inc (AQST) has around 135 employees, a market worth around $366.18M and $50.58M in sales. Profit margin for the company is -15.56%. Distance from 52-week low is 270.00% and -34.67% from its 52-week high.
Aquestive Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.08 with sales reaching $12.46M over the same period.The EPS is expected to shrink by -185.58% this year, but quarterly earnings will post 14.60% year-over-year. Quarterly sales are estimated to grow 11.90% in year-over-year returns.
64 institutions hold shares in Aquestive Therapeutics Inc (AQST), with institutional investors hold 29.41% of the company’s shares. The shares outstanding are 89.97M, and float is at 76.25M with Short Float at 2.98%. Institutions hold 27.93% of the Float.
The top institutional shareholder in the company is Bratton Capital Management, LP with over 9.81 million shares valued at $16.19 million. The investor’s holdings represent 14.70% of the AQST Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 1.56 million shares valued at $2.57 million to account for 2.34% of the shares outstanding. The other top investors are Renaissance Technologies, LLC which holds 1.23 million shares representing 1.84% and valued at over $2.03 million, while Armistice Capital, LLC holds 1.74% of the shares totaling 1.16 million with a market value of $1.91 million.
Aquestive Therapeutics Inc (AQST) Insider Activity
The most recent transaction is an insider sale by Schobel Alexander Mark, the company’s Chief Innovation/Tech Officer. SEC filings show that Schobel Alexander Mark sold 50,000 shares of the company’s common stock on Mar 15 ’24 at a price of $6.00 per share for a total of $0.3 million. Following the sale, the insider now owns 0.98 million shares.
Aquestive Therapeutics Inc disclosed in a document filed with the SEC on Mar 08 ’24 that Schobel Alexander Mark (Chief Innovation/Tech Officer) sold a total of 25,000 shares of the company’s common stock. The trade occurred on Mar 08 ’24 and was made at $5.19 per share for $0.13 million. Following the transaction, the insider now directly holds 1.04 million shares of the AQST stock.
